Vimarsana
Biggest News Aggregation in the World

Melissa Forst News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Melissa Forst. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Melissa Forst Today - Breaking & Trending Today

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting - Vimarsana News

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr 22, 2024--

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer - Vimarsana News

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial developmentWALTHAM, Mass., April 08, 2024 -- TScan Therapeutics, Inc. , a clinical-stage...

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer in the...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing - Vimarsana News

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and...

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split - Vimarsana News

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

GAITHERSBURG, Md., March 28, 2024 -- Cartesian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced results from a...